AML17 trial update: FLT3-ITD mutation and daunorubicin dosage
Reducing the risks of chemotherapy in IGHV-mutated CLL
MOR208: an effective drug for the treatment of CLL
What leads to shorter progression-free survival in CLL patients?
The future of treating acute leukemias